ArticleClinical, cosmetic and investigational dermatology2026
Ex vivo Evaluation of Live-MB2 and CX-2 Biotic Strains on Inflammatory and Barrier-Related Biomarkers in a Human Skin Atopic Dermatitis-Like Model.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by epidermal barrier disruption and immune dysregulation. Live-MB2 and CX-2 were used in an ex vivo human skin AD-like model, which provides a biologically relevant platform for assessing cosmetic ingredients targeting AD-like features. Methods: An AD-like condition was induced in ex vivo human skin explants by repeated tape stripping followed by 2,4-dinitrochlorobenzene stimulation. Skin tissues were treated with Live-MB2 or CX-2 via topical or dermal exposure. Epidermal thickness, IgE, and filaggrin levels were evaluated using hematoxylin and eosin, immunofluorescence, and Enzyme-Linked Immunosorbent Assay analyses. Results: Topical application of Live-MB2 and CX-2 significantly reduced epidermal thickness compared with AD-induced controls. IgE levels were significantly reduced, while filaggrin expression indicated a marked increase, indicating barrier recovery. No treatment-related tissue damage was observed. Conclusion: Live-MB2 and CX-2 showed favorable effects on inflammatory and barrier-related parameters in an ex vivo human skin AD-like model, supporting their potential application as cosmetic ingredients for sensitive and atopic-prone skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.